Medline Q4 2025 non-GAAP EPS $-0.01 miss, revenue $7.8B beat, completes IPO

 

Medline reports Q4 2025 results with non-GAAP EPS $-0.01 miss, revenue $7.8B beat, completes initial public offering

• Q4 2025 net sales rose 14.8% to $7.8B, while net income declined 37.7%.
• Company issued 2026 guidance for 8–9% organic sales growth and adjusted EBITDA of $3.5–$3.6 billion.
• Q4 2025 results and IPO completion were disclosed in an SEC report filed earlier today.

https://finviz.com/quote.ashx?t=MDLN&p=d